Skip to content Skip to footer
VIEWPOINTS_Dr. Philip M. Toleikis_2023

Dr. Philip M. Toleikis, President & CEO at Sernova Shares Insights on the Partnership with Evotec to Develop a ‘Functional Cure’ for Diabetes

Shots:  Dr. Philip shared his views on the collaboration of Sernova with Evotec for iPSC-Based Beta cell replacement therapy to develop and commercialize a ‘Functional Cure’ for diabetes.   He also gave an overview on the benefits of Evotec’s iPSC-based insulin-producing beta cells on the next generation of Sernova’s Cell Pouch System  The interview discusses about how Sernova…

Read more

VIEWPOINTS_Toni R. Hofhine_2023

Toni R. Hofhine, President of ATCOR Medical (CardieX) Shares Insights from Pulse- a New at-home Heart Health Monitor

Shots: Toni spoke about the CONNEQT Pulse the first dual blood pressure monitor with ATCOR’s SphygmoCor technology. The device is used for remote patient monitoring, home health, and clinical trials  She also elaborated about the data used for the pre-marketing submission with FDA. She explained the seven key vascular biomarkers that the device measures and…

Read more

VIEWPOINTS_John Gabrielson_2023

John Gabrielson SVP, Biosimilars & Head of Business of Similis Bio (JSR Life Sciences) Shares Insights on the Partnership with Blau Farmaceutica to Co-Develop Four Biosimilar Programs

Shots:  John spoke about the agreement between Similis Bio (a biosimilar partner and affiliate company of JSR) and Blau Farmaceutica to develop products and license IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders Under the collaboration, Similis Bio will provide full processes and associated IP for tech transfer to Blau…

Read more

Exclusive_Stacey Williams_2023

Stacey Williams, Vice President, Marketing, Dermavant Shares Insights on New Campaigns for Adults with Plaque Psoriasis

Shots: Stacey talked about the launch of its first streaming commercial as part of a direct-to-consumer advertising campaign for adults with plaque psoriasis The “Topical Uprising” campaign focuses on the patient journey and taps into the frustrations & self-conscious of living with plaque psoriasis that helps patients to demand more from their topical plaque psoriasis treatment The…

Read more

VIEWPOINTS_Dr. Richard Philipson_2023

Dr. Richard Philipson, CMO at Calliditas Shares Results & Insights from P-III Study Evaluating Tarpeyo

Shots:  Dr. Richard talked about the results from the NefIgArd P-III trial evaluating Tarpeyo (Nefecon) for the treatment of IgA Nephropathy  He also highlighted the safety and efficacy results from the NefIgArd study. He also spoke more about Trapeyo and the roadmap for its global approval and commercialization  The interview shows up how Calliditas is…

Read more

VIEWPOINTS_Dr. Jeff Cleland_2023

Dr. Jeff Cleland, CEO & President at Ashvattha Therapeutics Shares his Views From First Patient Enrolled for the Treatment of AMD and DME

Shots: Jeff spoke about the first patient enrolled in a P-II study of D-4517.2 for the treatment of wet AMD and DME Jeff also talked about Ashvatta’s Hydroxyl Dendrimer Platform and how this technology is beneficial to treat AMD and DME The interview gives a profound understanding of how Ashvattha is developing hydroxyl dendrimer therapeutics…

Read more

Viewpoints_Dr. Barbara Delage_Dr. Nicholas Kassebaum

Dr. Barbara Delage and Dr. Nicholas Kassebaum Shares Insights on Malnutrition-related Deaths

Shots: Dr. Barbara Delage talked about the key findings from the new study on malnutrition-related deaths. She also spoke about the birth condition, Orofacial cleft Dr. Nicholas Kassebaum spoke about how malnutrition-related deaths could be prevented in children living with a cleft The study was conducted in collaboration with Smile Train and the Institute for…

Read more

Viewpoints_Michael Irizarry

Michael Irizarry, SVP, Clinical Research, Eisai Shares Insights from the Clinical Data of Lecanemab Presented at AAIC

Shots: Michael talked about the new data from its Alzheimer’s pipeline at the Alzheimer’s Association International (AAIC) Michael also highlighted the study design of the P-II & P-III trial evaluating lecanemab The interview gives an understanding of  Eisai’s human health care (hhc) concept which provides innovative products with high unmet medical needs to target diseases…

Read more